Posted by Michael Wonder on 24 Oct 2020
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
23 October 2020 - Canadian government to provide $173M in funding for vaccine research and development, and domestic manufacturing capacity.
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce that it has reached an agreement to supply the Government of Canada with up to 76 million doses of its vaccine against COVID-19, subject to Health Canada approval.
Medicago will also receive $173M in funding support from the Government of Canada for its vaccine research and development, and for the construction of its Quebec City manufacturing facility.
